The glaucoma research community and FDA look to the future: A report from the NEI/FDA CDER glaucoma clinical trial design and endpoints symposium

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 4, 2009, Pages 1497-1505

  Weinreb, Robert N ^a   Kaufman, Paul L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APRACLONIDINE; DIPIVEFRINE; DORZOLAMIDE; LATANOPROST; PILOCARPINE; TIMOLOL; ANTIHYPERTENSIVE AGENT;

ARTICLE; CLINICAL RESEARCH; CONFOCAL LASER MICROSCOPY; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; KERATOMILEUSIS; MEDICAL RESEARCH; MEDICAL SOCIETY; OPTIC DISK; OPTIC NERVE; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PERIMETRY; POLARIMETRY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RETINA NERVE CELL; RISK FACTOR; SYMPOSIUM; VISION; VISUAL FIELD; BIOASSAY; CLINICAL TRIAL; CONFERENCE PAPER; METHODOLOGY; NATIONAL HEALTH ORGANIZATION; OPHTHALMOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; STANDARD; TREATMENT OUTCOME; UNITED STATES; VISUAL ACUITY;

ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS AS TOPIC; ENDPOINT DETERMINATION; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; NATIONAL INSTITUTES OF HEALTH (U.S.); OPHTHALMOLOGY; PRODUCT SURVEILLANCE, POSTMARKETING; QUALITY OF LIFE; RESEARCH DESIGN; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VISUAL ACUITY;

EID: 64049094496     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-2843     Document Type: Article

References (13)

1. Greve EL, Weinreb RL. Glaucoma Diagnosis: Structure and Function. The Hague, The Netherlands; 2004.
2. Lin SC, Singh K, Jampel HD, et al. American Academy of Ophthal mology, Ophthalmic Technology Assessment Committee Glaucoma Panel. Optic nerve head and retinal nerve fiber layer analysis: a report by the American Academy of Ophthalmology. Ophthalmology. 2007;114:1937-1949.
3. Greenfield DS, Weinreb RN. Perspectives: role of optic nerve imaging in glaucoma clinical practice and clinical trials. Am J Ophthalmol. 2008;145:598-603.
4. Budenz DL, Anderson DR, Feuer WJ, et al. Detection and prognostic significance of optic disc hemorrhages during the Ocular Hypertension Treatment Study. Ophthalmology. 2006;113:2137-2143.
5. Chauhan BC, McCormick TA, Nicolela MT, Leblanc RP. Optic disc and visual field changes in a prospective longitudinal study of patients with glaucoma: comparison of scanning laser tomography with conventional perimetry and optic disc photography. Arch Ophthalmol. 2001;119:1492-1499.
6. Zangwill LM, Weinreb RN, Beiser JA, et al. Baseline topographic optic disc measurements are associated with the development of primary open-angle glaucoma: the Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. Arch Ophthalmol. 2005;123:1188-1197.
7. Nicolela MT, McCormick TA, Drance SM, Ferrier SN, Leblanc RP, Chauhan BC. Visual field and optic disc progression in patients with different types of optic disc damage: a longitudinal prospective study, Ophthalmology. 2003;110:2178-2184.
8. Lalezary M, Medeiros FA, Weinreb RN, et al. Baseline optical coherence tomography predicts the development of glaucomatous change in glaucoma suspects. Am J Ophthalmol. 2006;142:576-582.
9. Mohammadi K, Bowd C, Weinreb RN, Medeiros FA, Sample PA, Zangwill LM. Retinal nerve fiber layer thickness measurements with scanning laser polarimetry predict glaucomatous visual field loss. Am J Ophthalmol. 2004;138:592-601.
10. Artes PH, Chauhan BC. Longitudinal changes in the visual field and optic disc in glaucoma. Prog Retin Eye Res. 2005;24:333-354.
11. Patterson AJ, Garway-Heath DF, Strouthidis NG, Crabb DP. A new statistical approach for quantifying change in series of retinal and optic nerve head topography images. Invest Ophthalmol Vis Sci. 2005;46:1659-1667.
12. World Health Organization Quality of Life Group. Study protocol for the World Health Organization project to develop a quality of life assessment instrument (WHOQOL). Qual Life Res. 1993;2: 153-159.
13. U.S. FDA Center for Biologics Evaluation and Research. Draft Guidance for Industry: Patient-Reported Outcome Measures-Use in Medical Product Development to Support Labeling Claims. Available at www.fda.gov/CBER/gdlns/prolbl.htm. Rockville, MD: U.S. Food and Drug Administration. Latest update: February 24, 2006.